Diazoxide improves hormonal counterregulatory responses to acute hypoglycemia in long-standing type 1 diabetes

Area of Science:

• Endocrinology
• Metabolic Disorders
• Neuroscience

Background:

• Individuals with long-standing type 1 diabetes (T1D) face severe hypoglycemia risks due to impaired glucose counterregulatory responses (CRRs).
• Current hypoglycemia prevention strategies are often insufficient, necessitating novel therapeutic approaches.
• Hypothalamic ATP-sensitive potassium (KATP) channels are implicated in hypoglycemia detection and CRR initiation, but human data are lacking.

Purpose of the Study:

• To investigate if the KATP channel activator diazoxide can enhance CRRs to hypoglycemia in T1D subjects with long-duration diabetes.
• To confirm the role of hypothalamic KATP channels in human CRRs during hypoglycemia.

Main Methods:

• A randomized, double-blind, placebo-controlled crossover trial was conducted.
• A stepped hyperinsulinemic hypoglycemia clamp was used in 12 T1D subjects.
• Participants received either diazoxide (7 mg/kg) or placebo prior to the clamp.

Main Results:

• Diazoxide significantly increased plasma epinephrine (37%) and norepinephrine (44%) levels during hypoglycemia compared to placebo.
• A subgroup analysis indicated that the E23K polymorphism in the KATP channel blunted the response to oral diazoxide.
• This study provides the first human evidence for KATP channel involvement in CRRs.

Conclusions:

• KATP channel activators, like diazoxide, show potential for improving CRRs to hypoglycemia in T1D.
• Therapeutic strategies for T1D hypoglycemia may be stratified based on KATP channel genotype (e.g., E23K polymorphism).
• This research opens avenues for personalized medicine in managing T1D complications.